| Literature DB >> 12657248 |
Yung- Wu Chen1, Morey L Smith, Grace X Chiou, Stephen Ballaron, Michael P Sheets, Earl Gubbins, Usha Warrior, Julie Wilkins, Carol Surowy, Masaki Nakane, George W Carter, James M Trevillyan, Karl Mollison, Stevan W Djuric.
Abstract
In order to discover novel immunomodulators for application in treating autoimmune diseases, a stable Jurkat transfectant was constructed in which luciferase reporter gene is driven by a full-length IL-2 promotor. A chemical library was screened to identify compounds that inhibited luciferase expression in Jurkat transfectants stimulated with PMA and ionomycin. A class of compounds (bis-trifluoromethyl pyrazole, BTPs) was identified from this screen. BTPs were shown to inhibit anti-CD3 and anti-CD28 antibody-induced IL-2 secretion, mixed lymphocyte reaction, and Con A-induced T cell proliferation in normal human peripheral blood T cells. In addition, mRNA levels of IL-4, IL-5, IL-9, IL-10, IL-13, IL-15, and IFN-gamma were markedly inhibited by BTPs in peripheral blood mononuclear cells stimulated by Con A as determined by multi-probe RNA protection assay. Furthermore, IL-2, IL-4, IL-5, and IFN-gamma secretion by Hut 78 cells or CD3(+) T cells stimulated with PMA plus ionomycin or anti-CD3 antibody plus PMA were inhibited in a concentration-dependent manner by BTPs. Therefore, BTPs inhibit a wide spectrum of cytokine production including TH1 and TH2 type cytokines. Taken together, these compounds may be useful for treating autoimmune diseases and organ transplant rejection.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12657248 DOI: 10.1016/s0008-8749(03)00005-4
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868